Market Overview

The Medicines Co., Bristol-Myers Begin Alliance for Recothrom

Related MDCO
Alexion Pharmaceuticals Q2 Earnings In Line; Revises View
Medicines (MDCO) is Oversold: Can It Recover? - Tale of the Tape
Related BMY
Bristol-Myers Squibb Co In Patent Suit Vs. Merck & Co., Inc. Over Skin Cancer Drug
Markets Little Changed In Low Volume And Slow News Ahead Of Long Weekend
The Stocks Already in Correction Mode (Fox Business)

The Medicines Company (NASDAQ: MDCO) announced today that the global license and two-year collaboration for Recothrom(R), a recombinant thrombin approved by the U.S. Food and Drug Administration for use as a topical hemostat to control non-arterial bleeding during surgical procedures, established with Bristol-Myers Squibb Company (NYSE: BMY) has become effective. The agreement was first announced in December 2012. The companies have satisfied all required regulatory and closing conditions.

Posted-In: News

 

Related Articles (MDCO + BMY)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters